David Hoang
Stock Analyst at Deutsche Bank
(1.82)
# 3,134
Out of 4,944 analysts
40
Total ratings
36.67%
Success rate
-8.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $54 → $55 | $36.67 | +49.99% | 3 | Jul 10, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Hold | $50 → $25 | $20.40 | +22.55% | 7 | Jun 17, 2025 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $20 → $35 | $25.13 | +39.28% | 5 | May 21, 2025 | |
| ALKS Alkermes | Maintains: Buy | $40 → $52 | $28.63 | +81.63% | 2 | Mar 27, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $67 | $37.67 | +77.86% | 3 | Feb 11, 2025 | |
| PRAX Praxis Precision Medicines | Initiates: Buy | $111 | $49.05 | +126.30% | 1 | Feb 11, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $14.81 | +109.32% | 3 | Feb 11, 2025 | |
| BHVN Biohaven | Initiates: Buy | $65 | $14.39 | +351.70% | 1 | Feb 11, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $176 | $109.39 | +60.89% | 4 | Feb 11, 2025 | |
| AVDL Avadel Pharmaceuticals | Initiates: Buy | $12 | $13.77 | -12.85% | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $131.62 | +20.04% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.27 | +451.18% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $6.68 | +139.52% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $3.65 | +338.36% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $432.52 | -49.14% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $19.99 | +300.20% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $1.97 | +52.28% | 1 | Dec 7, 2022 |
Harmony Biosciences Holdings
Jul 10, 2025
Maintains: Buy
Price Target: $54 → $55
Current: $36.67
Upside: +49.99%
Sarepta Therapeutics
Jun 17, 2025
Maintains: Hold
Price Target: $50 → $25
Current: $20.40
Upside: +22.55%
ACADIA Pharmaceuticals
May 21, 2025
Upgrades: Buy
Price Target: $20 → $35
Current: $25.13
Upside: +39.28%
Alkermes
Mar 27, 2025
Maintains: Buy
Price Target: $40 → $52
Current: $28.63
Upside: +81.63%
Xenon Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $67
Current: $37.67
Upside: +77.86%
Praxis Precision Medicines
Feb 11, 2025
Initiates: Buy
Price Target: $111
Current: $49.05
Upside: +126.30%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $14.81
Upside: +109.32%
Biohaven
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $14.39
Upside: +351.70%
Axsome Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $109.39
Upside: +60.89%
Avadel Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $12
Current: $13.77
Upside: -12.85%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $131.62
Upside: +20.04%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $1.27
Upside: +451.18%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $6.68
Upside: +139.52%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $3.65
Upside: +338.36%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $432.52
Upside: -49.14%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $19.99
Upside: +300.20%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $1.97
Upside: +52.28%